US Pharma MarketingThe post Patient enrolment concludes in Alebund’s Phase III trial of AP301 appeared first on Clinical Trials Arena.
Patient enrolment concludes in Alebund’s Phase III trial of AP301
Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial of AP301 for hyperphosphatemia. The study involved CKD patients aged 12 years and above, enrolling 282 patients instead of the planned 264. Existing data led to FDA agreement that the global Phase III trial can serve as the single pivotal registration study. Credit: SaiArLawKa2 / Shutterstock.com. Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial, RESPOND-2, Study AP301-HP-03, evaluating the fibre-iron-based phosphate binder AP301 for hyperphosphatemia. The multi-regional, randomised, double-blind trial enrolled 282 chronic kidney disease patients on maintenance dialysis, with…
Alebund Pharmaceuticals has completed patient enrolment in its global Phase III pivotal clinical trial of AP301 for hyperphosphatemia.
Source: Clinical Trials Arena